Harmony Biosciences Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Harmony Biosciences reported 3rd quarter 2026 net revenue of $269 million, compared with $239 million in the prior-year quarter, and net income of $48 million, or $0.81 per diluted share, compared with $51 million, or $0.87 per diluted share.
- WAKIX had approximately 9,350 average patients in the quarter, adding 400 net patients; management said it recorded 400 or more net patient additions in 5 of the last 6 quarters.
- Cost of products sold was 30% of net revenue, compared with 25% 1 year ago; total operating expenses were $134 million, compared with $114 million.
- The year-over-year increase in operating expenses included a $25 million charge related to an MSN Labs milestone, continued R&D investment, and field-team expansion, partly offset by a $15 million ZYN002 clinical milestone charge in the prior-year quarter.
- Harmony ended the quarter with over $1 billion of cash, cash equivalents, and investments, and $150 million in debt.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star 0, and a member of our team will be happy to help you. Please stand by. Your meeting is about to begin. Good morning. My name is Nikki, and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences' third quarter financial results conference call. All participant lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question at that time, please press star one on your telephone keypad. Please be advised that today's conference is being recorded. Lastly, if you should require operator assistance, please press star 0.
I will now turn the call over to Brennan Doyle, head of investor relations.
Please go ahead. Thank you, operator.
Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences' third quarter 2026 financial results and provide a business update. Before we start, I encourage everyone to go to the investors section of our website to find the materials that accompany today's discussion. Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; Peter Anastasiou, Senior Executive Vice President, Chief Operating Officer, and incoming President and CEO; Adam Zaeske, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical and Scientific Officer; Steve Mollichella, Interim Principal Financial Officer. As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to risk and uncertainties. Our actual results may differ materially, and we undertake no obligation to update these statements even if circumstances change.
We encourage you to consult the risk factors referenced in our SEC filings for additional details. I would now like to turn the call over to our CEO, Dr. Jeffrey Dayno.
Jeff. Thank you, Brennan. Good morning, everyone, and thank you for joining our call today.
Before I get into the quarter, I first want to say a few words about the CEO transition we announced last month. I will be stepping down at the end of the year, and Peter Anastasiou, our Senior Executive Vice President and Chief Operating Officer, will succeed me as President and Chief Executive Officer effective January 1st, 2027. I am confident that Harmony is in very good hands with Peter, and you will hear from him next. The main themes regarding the CEO transition are continuity, strength, and growth. This leadership transition does not signal any change in our overall business or our strategic priorities. We are doing this from a position of strength and executing a well-coordinated plan.
Harmony continues to be a growth story, and during Q3, we moved that story forward in each of our four priorities of value creation: continue to grow WAKIX in an evolving market, advancing a novel and robust clinical-stage pipeline, transact on strategic business development deals, and protect the pitolisant franchise. I will provide some more color on our first two strategic priorities of value creation and then turn it over to Peter to expand on our other two strategic priorities. The key highlights that I want you to take away from today's call are sustained patient demand-driven growth for WAKIX in its seventh year on the market, keeping us firmly on track to exceed $1 billion in net revenue this year, and preliminary multiple ascending dose data for our orexin-2 agonist, BP-205, that further strengthen its emerging best-in-class profile. First, growing the WAKIX franchise.
In the third quarter, WAKIX delivered $269 million in net revenue with 400 net patient adds, resulting in approximately 9,350 average patients on WAKIX in the quarter. For the first time in company history, we expect to exceed $1 billion in revenue for WAKIX this year. We want to recognize our commercial team for their executional excellence, and Adam will take you through our commercial performance in more detail later in the call. Our second strategic priority is advancing our novel clinical-stage pipeline. The strength and durability of the pitolisant franchise gives us the flexibility to fund our pipeline, creating new growth drivers for the company. The centerpiece of our pipeline is BP-205, and we continue to have firm conviction in its best-in-class potential. Today, we announced preliminary results from the multiple ascending dose portion of our phase I study for BP-205.
After 14 days of once-daily dosing, the safety, tolerability, and PK profile was consistent with what we saw in the single ascending dose study, giving us confidence in the emerging best-in-class profile of BP-205. We initiated a study in sleep-deprived healthy volunteers in the third quarter, with data expected in the first quarter of 2027. Phase II studies across multiple CNS indications are planned to initiate in mid-2027. There is a clear line of sight to the multiple data catalysts for BP-205, and they are right around the corner. Kumar will provide more color on BP-205 and the rest of our pipeline programs during his R&D update. Peter will now walk you through our two other value creation priorities related to business development and protecting the pitolisant franchise.
Peter? Thank you, Jeff, and good morning, everyone.
First, I want to thank Jeff for his leadership and for everything he has done for Harmony over the last nine years. WAKIX is on track to exceed $1 billion in net revenues this year, we have a novel pipeline led by BP-205, and we have a strong balance sheet to fund our business development efforts. That is the foundation I get to build on, and I am honored to become Harmony's next CEO. Our ambition is to build Harmony into an enduring, leading CNS company with multiple products across multiple franchises, and our strategic priorities will enable us to achieve this ambition. You heard Jeff speak to our first two strategic priorities regarding our strength in the WAKIX business and the advancement of our pipeline. Our third strategic priority is transacting on business development.
With over $1 billion on our balance sheet, we have both the capacity and the conviction to execute on meaningful transactions. We are pursuing assets that can add near-term revenues to support our self-funded model and assets that can continue to drive long-term value creation. Our fourth strategic priority is protecting the pitolisant franchise. We have settled with six of the seven ANDA filers, and our multi-layered IP strategy across active legal proceedings reinforces our confidence in WAKIX exclusivity to March 2030, inclusive of six months of pediatric exclusivity. In summary, Harmony is a growth story, and we are executing on all four strategic priorities. To tell you more about our first strategic priority of growing the WAKIX franchise, I'll turn it over to our Chief Commercial Officer, Adam Zaeske.
Adam? Thank you, Peter, and good morning, everyone.
We continue to see extremely strong demand-driven growth for WAKIX this quarter. WAKIX achieved estimated average patients of 9,350, an increase of 400 patients in the quarter. WAKIX has now demonstrated a meaningful acceleration in growth in year seven on the market, with 400 net patient additions in five of the last six quarters. Prior to 2025, WAKIX had achieved 400 net patient additions only twice in the history of the brand. As a result, WAKIX delivered $269 million in net product revenue, which was right in line with our internal expectation, and we remain on track to achieve our full-year guidance of $1 billion-$1.04 billion. The drivers of this growth and performance are clear. WAKIX holds a unique position as the only non-scheduled treatment option for excessive daytime sleepiness and cataplexy in adults and pediatric patients with narcolepsy.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
17 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
